- Home
- RPAY vs ABVX Comparison
RPAY vs ABVX Comparison
Compare RPAY & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPAY
- ABVX
- Stock Information
- Founded
- RPAY 2006
- ABVX 2013
- Country
- RPAY United States
- ABVX France
- Employees
- RPAY N/A
- ABVX N/A
- Industry
- RPAY Business Services
- ABVX
- Sector
- RPAY Consumer Discretionary
- ABVX
- Exchange
- RPAY Nasdaq
- ABVX Nasdaq
- Market Cap
- RPAY 387.2M
- ABVX 451.5M
- IPO Year
- RPAY N/A
- ABVX N/A
- Fundamental
- Price
- RPAY $3.98
- ABVX $6.96
- Analyst Decision
- RPAY Buy
- ABVX Strong Buy
- Analyst Count
- RPAY 8
- ABVX 5
- Target Price
- RPAY $9.69
- ABVX $33.80
- AVG Volume (30 Days)
- RPAY 1.8M
- ABVX 100.3K
- Earning Date
- RPAY 05-12-2025
- ABVX 03-24-2025
- Dividend Yield
- RPAY N/A
- ABVX N/A
- EPS Growth
- RPAY N/A
- ABVX N/A
- EPS
- RPAY N/A
- ABVX N/A
- Revenue
- RPAY $313,042,000.00
- ABVX $11,172,999.00
- Revenue This Year
- RPAY $0.54
- ABVX $284.20
- Revenue Next Year
- RPAY $7.52
- ABVX N/A
- P/E Ratio
- RPAY N/A
- ABVX N/A
- Revenue Growth
- RPAY 5.53
- ABVX 135.94
- 52 Week Low
- RPAY $3.59
- ABVX $4.77
- 52 Week High
- RPAY $11.27
- ABVX $14.75
- Technical
- Relative Strength Index (RSI)
- RPAY 38.14
- ABVX 55.03
- Support Level
- RPAY $3.59
- ABVX $6.54
- Resistance Level
- RPAY $4.57
- ABVX $7.83
- Average True Range (ATR)
- RPAY 0.21
- ABVX 0.52
- MACD
- RPAY 0.04
- ABVX 0.01
- Stochastic Oscillator
- RPAY 39.80
- ABVX 43.89
About RPAY Repay Holdings Corporation
Repay Holdings Corp is engaged in providing integrated payment processing solutions to verticals that have transaction processing needs. It allows customers to pay through Mobile App, Text, Interactive Voice Response, Virtual Terminal, Hosted Payment Page and Online Customer Portal among others. It operates in two segments Consumer Payments and Business Payments.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.